logo
Twitter
Discord
Email
logo
CureVac N.V.

CureVac N.V.

NASDAQ•CVAC
CEO: Dr. Alexander Zehnder M.B.A., M.D.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2020-08-14
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.
Contact Information
Friedrich-Miescher-Strasse 15, Tübingen, 72076, Germany
49-7071-9883-0
www.curevac.com
Market Cap
$947.98M
P/E (TTM)
4.1
40.8
Dividend Yield
--
52W High
$5.72
52W Low
$2.48
52W Range
53%
Rank71Top 96.3%
1.4
F-Score
Modified Piotroski Analysis
Based on 7-year fundamentals
Weak • 1.4 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2018-2024

Financial Dashboard

Q3 2025 Data

Revenue

$575.78M+0.00%
4-Quarter Trend

EPS

$1.75-0.66%
4-Quarter Trend

FCF

$0.00+0.00%
4-Quarter Trend

2024 Annual Earnings Highlights

Key Highlights

Significant Revenue and Profit Turnaround Revenue reached €535.18M in 2024, up 896% from €53.8M; achieved Net Profit of €162.19M after prior losses.
Strong Cash Position Maintained Cash and equivalents totaled €481.75M as of December 31, 2024, supporting operations through at least 2028.
Oncology Candidate Shows Promise CVGBM Phase 1 data showed 77% of evaluable patients achieved cancer antigen-specific T-cell responses.

Risk Factors

Continued Operating Losses Expected Accumulated deficit reached €1.404B; expects continued losses despite 2024 profit, requiring substantial future financing.
Clinical Trial Data Uncertainty Preliminary clinical trial data are subject to audit and verification, potentially causing material changes to final results.
Intellectual Property Litigation Risk Ongoing, expensive patent litigation with BioNTech, including adverse rulings like one patent revocation in Germany.
Manufacturing Complexity Risks Complex mRNA manufacturing processes face risks from contamination, supply chain issues, and scaling difficulties.

Outlook

Advance UPEC Program to Clinic Expect filing IND application for UPEC UTI candidate in H2 2025, aiming to initiate Phase 1 study in H1 2026.
Focus on High-Value Pipeline Strategic restructuring aims to increase efficiency, focusing capital resources on high-value mRNA projects in oncology and infectious diseases.
CVGBM Phase 2 Decision Pending Initial data readout and decision on advancing CVGBM oncology program to Phase 2 expected in the second half of 2025.

Peer Comparison

Revenue (TTM)

Novavax, Inc.NVAX
$1.06B
+20.3%
CureVac N.V.CVAC
$567.03M
-5.9%
Ardelyx, Inc.ARDX
$398.23M
+58.1%

Gross Margin (Latest Quarter)

Immatics N.V.IMTX
100.0%
+0.0pp
Immunome, Inc.IMNM
100.0%
+0.0pp
Ardelyx, Inc.ARDX
98.8%
+14.8pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
NUVB$3.19B-15.0-55.0%1.7%
WVE$2.87B-24.7-72.9%76.4%
IMNM$1.99B-9.0-87.4%1.4%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
234.2%
Strong Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention

Research & Insights

Next earnings:Apr 9, 2026
|
EPS:-$0.08
|
Revenue:-
Reports
All Years

  • Form 20-F - FY 2024

    Period End: Dec 31, 2024|Filed: Apr 11, 2025|
    Revenue: $578.95M+895.5%
    |
    EPS: $0.78+161.0%
    Beat

  • Form 20-F - FY 2023

    Period End: Dec 31, 2023|Filed: Apr 25, 2024|
    Revenue: $58.15M-20.3%
    |
    EPS: $-1.28+10.6%
    Miss

  • Form 20-F/A - FY 2022

    Period End: Dec 31, 2022|Filed: Oct 12, 2023|
    Revenue: $71.64M-34.5%
    |
    EPS: $-1.40+40.3%
    Miss

  • Form 20-F - FY 2022

    Period End: Dec 31, 2022|Filed: Apr 25, 2023|Refer to amended data

  • Form 20-F - FY 2021

    Period End: Dec 31, 2021|Filed: Apr 28, 2022|
    Revenue: $121.78M+110.6%
    |
    EPS: $-2.61-125.5%
    Miss

  • Form 20-F - FY 2020

    Period End: Dec 31, 2020|Filed: Apr 27, 2021|
    Revenue: $55.77M+180.8%
    |
    EPS: $-1.12-84.9%
    Meet